Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUNAR-2: TTFields with Pembrolizumab and Chemotherapy in Metastatic NSCLC
NCT06216301Phase 3Recruiting
- Sponsor
- NovoCure
- Start
- Jul 2024
- Primary completion
- Oct 2028
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by NovoCure. Primary endpoints: Overall Survival at 6 years and Progression-Free Survival at 6 years. Started Jul 2024; status: recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06216301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06216301.